Sort
48,018 grants matching “immunotherapy”
Novel mechanisms regulating PD-1 signaling and function
$442,212Adam Mor · Columbia University Health Sciences · R01 · FY2022 · AI
From the Past to the Future: Chimeric Antigen Receptor T cells for Lymphoid Malignancies
$442,180Joseph Anthony Fraietta · University Of Pennsylvania · P01 · FY2023 · CA
Molecular characterization and modeling efficient antibody effector function
$442,024Margaret E Ackerman · Dartmouth College · R01 · FY2025 · AI
Humanized mouse models to dissect in vivo the interplay between melanoma and the immune system
$442,010Anna Karolina Palucka · Jackson Laboratory · R01 · FY2016 · CA
Development of a Vaccine Approach to Inhibit Atherosclerosis
$442,003Joseph L Witztum · University Of California, San Diego · R01 · FY2010 · HL
Project 3
$441,978Richard G Vile · Mayo Clinic Rochester · P50 · FY2024 · CA
Overcoming vaccine-associated hypoxia with advanced biomaterials to enhance cancer immunotherapy
$441,967Stephen Matthew Hatfield · Northeastern University · R01 · FY2024 · EB
Structural and Functional Roles of the Membrane-Related Components of Single-Pass Membrane Proteins
$441,960James J Chou · Harvard Medical School · R35 · FY2022 · GM
HIV Molecular Biology and Pathogenic Mechanisms of AIDS
$441,926George N. Pavlakis · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Defining epigenetic signaling to reshape pancreatic tumor microenvironment
$441,899Jiaqi Shi · University Of Michigan At Ann Arbor · R37 · FY2024 · CA
Metabolic Barriers to T Cell Activation in Clear Cell Renal Cell Carcinoma
$441,879Jeffrey C Rathmell · Vanderbilt University Medical Center · R01 · FY2020 · CA
Elucidating the role of RXRA in the myeloid lineage in post-infectious basal ganglia encephalitis
$441,853Dritan Agalliu · Columbia University Health Sciences · R21 · FY2022 · NS
UCLA Tumor Immunology Training Program
$441,837Michael A Teitell · University Of California Los Angeles · T32 · FY2015 · CA
Enhancing Tumor Antigen Presentation with Complement Targeted Nanoparticles
$441,796Max Peter Kullberg · University Of Alaska Anchorage · R15 · FY2022 · CA
Tumor and Immune Programming of Tumor-Associated Endothelium
$441,760Eugene C Butcher · Palo Alto Veterans Instit For Research · R01 · FY2021 · CA
Project 3: Chemokine modulation in TME for enhanced TLS formation and cross-priming/ recruitment of therapeutic CD8+ TILs
$441,751Walter J Storkus · Roswell Park Cancer Institute Corp · P01 · FY2021 · CA
Overcoming primary and secondary resistance in wild-type BRAF melanoma
$441,736Andrew E Aplin · Wistar Institute · P01 · FY2023 · CA
Targeting the FBXO44/SUV39H1 Pathway in Cancer
$441,716Charles H Spruck · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2022 · CA
Targeting ER+ Breast Cancer Through Induced Viral Mimicry
$441,716Charles H Spruck · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2022 · CA
Regulation of Tumor Immunogenicity in Glioblastoma
$441,658Sze Chun Winson Ho · University Of California, San Francisco · R01 · FY2024 · NS
Lymphoid residency of Tcf-1+ CD8+ T cells during tumor vaccine responses
$441,601Nu Zhang · University Of Texas Hlth Science Center · R01 · FY2024 · AI
CELL SURFACE ANTIGENS--TRANSFERRIN RECEPTORS
$441,517Salk Institute For Biological Studies · R01 · FY2000 · AI
Targeting NQO1+ tumor to trigger innate and adaptive immunity
$441,498Xiumei Huang · Indiana University Indianapolis · R01 · FY2023 · CA
MHC-Restricted and MHC-Non-Restricted Targeting of Ovarian Cancer by alphaDC1
$441,496Pawel Kalinski · Roswell Park Cancer Institute Corp · P50 · FY2014 · CA
Immunobiology of Myeloid and Lymphoid Cells
$441,467Edward John Usherwood · Dartmouth College · T32 · FY2022 · AI